It has been a while since the launch of new drugs in the retina space. However, 2023 will see several launches. Many practices have not been through a new drug launch and are apprehensive about billing J3490 Unclassified drugs or J3590 Unclassified biologics1 while awaiting the permanent J-code, or in the case of new biosimilars, a permanent Q-code. There are several central factors to consider when billing J3490 and J3590.